Please store the product under the recommended conditions in the Certificate of Analysis.
产品详情
Teclistamab 是一种人源化的 BCMA 和 CD3 双特异性抗体,可识别靶细胞上的 BCMA 和 T 细胞上的 CD3,诱导 T 细胞介导的细胞毒性,导致 T 细胞的活化和随后的靶细胞裂解。Teclistamab 可用于多发性骨髓瘤等相关疾病研究。
生物活性
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).
性状
Liquid
体外研究(In Vitro)
Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性,在 H929 细胞中的 EC50 值为 0.15 nM,在MM.1R 细胞系中为 0.06 nM,在 RPMI 8226 细胞系中为 0.45 nM。Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 人 BM 单核细胞,并诱导人 BM 单核细胞的细胞毒性。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG(NOD/SCID/γc)小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549.